A Michael Lincoff

发表

A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.

Robert M Califf, Paul W Armstrong, R. Califf, 2006, Journal of the American College of Cardiology.

The use and limitations of unfractionated heparin.

Christopher P Cannon, Amar Krishnaswamy, C. Cannon, 2010, Critical pathways in cardiology.

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.

N Franklin Adkinson, Jeffrey Sailstad, Paul W Armstrong, 2016, The Journal of allergy and clinical immunology.

Prevalence of conventional risk factors in patients with coronary heart disease.

Eric J Topol, E. Topol, E. Ohman, 2003, JAMA.

2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in

Hani Jneid, Robert M Califf, Charles R Bridges, 2011, Journal of the American College of Cardiology.

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc

Hani Jneid, Charles R Bridges, Theodore G Ganiats, 2012, Journal of the American College of Cardiology.

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c

Hani Jneid, Robert M Califf, Charles R Bridges, 2011, Journal of the American College of Cardiology.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Giuseppe Ambrosio, Claes Held, Marco Valgimigli, 2012, The New England journal of medicine.

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Matthias Herz, Markolf Hanefeld, M. Hanefeld, 2014, BMC Nephrology.

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist

A. Lincoff, Matthew A Cavender, M. Cavender, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

A. Lincoff, S. Nissen, S. Nicholls, 2007, JAMA.

2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Nancy M Albert, Hani Jneid, Robert M Califf, 2013, Journal of the American College of Cardiology.

Platelet inhibition with cangrelor in patients undergoing PCI.

Gregg W Stone, Deepak L. Bhatt, Deepak L Bhatt, 2009, The New England journal of medicine.